Merck stops study of HIV vaccine

Share this article:
A worldwide Phase II trial of a Merck HIV vaccine was halted after an independent reviewer found the vaccine ineffective, the firm said.

The trial of about 3,000 HIV-negative volunteers was being co-sponsored by Merck and the HIV Vaccine Trials Network (HVTN), the largest clinical trials program for developing and testing HIV vaccines which is part of the NIH.

Merck had been testing the drug for 10 years and, while the vaccine was not thought to have huge commercial potential, it was considered important in the global effort against the virus that causes AIDS. The best way to control the spread of the disease is thought to be through a prophylatic vaccine.

Had it worked, V520, as the vaccine was known internally, would have added to a string of R&D successes for Merck that also have included Gardasil, a vaccine against the virus that causes cervical cancer, and Januvia, a diabetes pill. Cordaptive, an extended-release niacin + flush inhibitor, was recently filed with the FDA.

“We share in the disappointment of the research and HIV communities today,” said Peter Kim, PhD, president, Merck Research Laboratories, in a statement. “Sadly, developing an effective AIDS vaccine remains one of the most challenging tasks facing modern medicine.”

According to Merck, the independent Data Safety Monitoring Board reviewed safety data and results of an interim efficacy analysis of the study, recommending discontinuation because the trial will not meet its efficacy endpoints.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...